Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From INBRAIN Neuroelectronics
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Medtech Insight spoke to two CEOs of start-ups working on graphene-based devices to learn more about how regulation and fears over nanomaterials’ side effects affect device development.
The biotech giant signed a commercial agreement with bioelectronics company Innervia, and the two will work collaboratively on vagus nerve stimulating technologies.
- Digital Health
- Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
- INNERVIA Bioelectronics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.